Success Story: Our Expert Team Secured NIW Success for A Scientist from Nepal with Premium Processing Service
Client’s Testimonial:
“Overall, I had a good experience working with Chen Associates.”
On February 6th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Scientist
Country of Origin: Nepal
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: February 6th, 2025
Processing Time: 1 month, 17 days (Premium Processing Requested)
Case Summary:
We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a cancer biology expert. The client, who holds a Ph.D. in cell biology, genetics, and molecular medicine, approached NAILG to seek approval for their proposed endeavor in the field of cancer precision medicine. At the time of filing, the client was employed as a senior scientist in translational medicine, continuing impactful work in cancer research.
Research Focus and Contributions:
The client’s research is centered on leveraging omics-based data, including genomic, transcriptomic, and proteomic analyses, to identify clinically actionable biomarkers for targeted precision medicine in cancer patients. Their work is crucial for advancing the development of personalized therapies, enabling better-targeted treatments and improving patient outcomes.
With 7 peer-reviewed journal articles, including 2 first-authored and 1 co-first-authored, the client’s research has already made a significant impact in the field. Their work has been cited 71 times, underscoring the relevance and influence of their contributions. The client’s research has also been supported by major funding agencies, including the NIH Cancer Systems Biology Consortium, NIH NCATS, and NIH NCI, which recognize the national importance of their work.
Well Positioned to Advance the Proposed Endeavor:
The client’s educational background and professional experience have positioned them to lead cutting-edge research in cancer biology. Their expertise in analyzing high-throughput sequencing data, including single-cell ATAC-seq and proteomics, has enabled them to provide valuable insights into cancer progression, tumor heterogeneity, and personalized treatment strategies. The client has authored influential publications in renowned journals, and their work has been cited extensively by researchers around the world. Additionally, the client serves as an editor for the Journal of Emerging Investigators, further establishing their authority in the field.
Support from Experts in the Field:
The petition was strengthened by two letters of recommendation from distinguished experts, which affirmed the client’s exceptional contributions to cancer research. The recommenders praised the client’s innovative use of omics-based technologies and highlighted the critical nature of their work in advancing precision oncology.
“With her strong foundation in both academic research and applied clinical science, she is exceptionally equipped to drive innovation in cancer treatment and patient care.”
NIW Approval and Outlook:The client’s EB-2 NIW petition was approved in February 2025, following its filing in December 2024. With this approval, the client is poised to continue their impactful research on identifying actionable biomarkers for cancer patients, contributing significantly to the field of precision medicine. NAILG is proud to have assisted the client in obtaining this approval and looks forward to their ongoing contributions to improving cancer treatment outcomes in the United States.